Rocket Lab’s NASA Bonanza Can’t Mask the 44% Rout — Investors Want Proof, Not Promises

Space is booming for Rocket Lab. The company just notched its twelfth launch of 2026, added two new NASA missions to its manifest, and sits on a $2.2 billion order backlog. Yet the stock has shed nearly 44% of its value in the past 30 days, closing Friday at €72.70. A meager 2.5% daily gain did little to arrest a slide that now leaves the shares roughly 46% below their May record.

The disconnect between operational momentum and market sentiment has seldom been wider. Rocket Lab’s Electron rocket delivered another satellite for Japanese customer Synspective over the weekend — the 91st mission overall — with a perfect success rate. The customer has already booked 17 more launches through the end of the decade. First-quarter revenue surged 63% to just over $200 million. None of it seems to matter.

Sector Gravity and Dilution Fears

Investors are fleeing space stocks en masse following the IPO of SpaceX, which has sucked capital out of the entire sector. Rocket Lab is also tapping a multibillion-dollar share sale program to fund its expansion, stoking dilution fears that compound the selling pressure. The stock’s 93% annualized volatility underscores the raw nerves.

The technical picture is ugly. The 50-day moving average now sits more than 21% above the current price, and the relative strength index has plunged to 35, deep in oversold territory. A bounce is possible, but the trend remains firmly downward.

Should investors sell immediately? Or is it worth buying Rocket Lab?

NASA Picks Rocket Lab for Two New Missions

Amid the wreckage, the U.S. space agency handed Rocket Lab a vote of confidence. NASA selected the company for the PolSIR and TSIS-2 projects, beginning in early 2027. The missions require three Electron launches, with reliability cited as the deciding factor. The contract adds to a federal portfolio that already includes defense and commercial work.

Another long-term catalyst is the Neutron rocket. Engine tests are underway, but any delays could quickly sour the mood. The backlog — now above $2.2 billion — provides a buffer, but it is future revenue, not current cash.

Earnings Season Looms

The next hard data point arrives in August, when Rocket Lab reports second-quarter results. Management has guided for revenue as high as $240 million, a sequential gain of 16%. Analysts remain broadly bullish: the consensus price target on Wall Street is $97.50, with KeyBanc at the top of the range at $135, recently upgrading the stock to “Overweight” on the view that the sector selloff has created an entry point.

The real test, however, is profitability. The company is targeting margins of up to 40%. If the August report shows that operational growth is outpacing the dilution from the equity program, the bears will lose their strongest argument. A strong second-half outlook could refocus investors on what Rocket Lab is doing in the sky rather than what is happening to its stock price.